Positron emission tomography with a 68Gallium-labeled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA-PET hybrid imaging) is a promising new diagnostic tool for staging prostate cancer, according to German urologists who presented their experience at the American Society of Clinical Oncology annual meeting in Chicago. Get results
Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.
Hear and get results from Neal Shore, MD, as he discusses with Crystal Murcia, PhD the surveys findings, explains why men aren’t speaking up about their prostate cancer symptoms, and urologists' role in assessing how patients are feeling.
The assay might help identify candidates for active surveillance, study authors say.
Economic, social, and cultural factors all have an impact on Americans’ access to effective infertility treatment, a new report states.
A new study underscores the long-term value of active surveillance for men with low- or very low-risk prostate cancer.
The opportunities for physicians in men’s health are tremendous. As with most career moves, blindly entering a field is ill advised. Rather, I recommend that the thoughtful young urologist carefully consider the following steps and pointers.
A novel treatment for the targeted removal of prostate tissue may soon be coming to a hospital near you. According to the results of a phase II study presented at the AUA annual meeting in New Orleans, Aquablation, a minimally invasive water ablation therapy, demonstrated efficient and precise resection of prostate tissue in patients with BPH.
In this video, the investigators demonstrate a promising technique using multiphoton microscopy to find tubules containing sperm during microsurgical testis sperm extraction.
The prostatic urethral lift (PUL [UroLift, NeoTract, Inc.]) yields successful 3-year durability and superior rate of improvement of BPH symptoms compared to transurethral resection of the prostate, according to separate studies presented at the AUA annual meeting in New Orleans.
The association between testosterone replacement therapy (TRT) and thrombotic risk in elderly men remains controversial. While the FDA has mandated that all approved testosterone products include warnings about a possible increase in cardiovascular, stroke, and venous blood clot risk, at least one study presented at the AUA annual meeting in New Orleans found no link between TRT and cardiovascular events.
This video describes and demonstrates two techniques for minimally invasive sperm retrieval appropriate for men with obstructive azoospermia.
In this round-up of new urology products and services, learn about the FDA approving an oral agent for HSDD, an app that helps men with erectile dysfunction, and more.
In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
The management of BPH has had an interesting roller coaster ride over the past 25 years with new medicines, minimally invasive surgical therapies, and a host of novel surgical technologies, including lasers and bipolar electrosurgery.
A handheld transurethral therapy that delivers targeted sterile water vapor reduces lower urinary tract symptom severity in patients with BPH with no impact on sexual function.
After accounting for the risk of reclassification, carefully monitored men with favorable-risk prostate cancer who enroll in active surveillance and undergo delayed surgery are no more likely to demonstrate adverse features associated with 15-year prostate cancer-specific mortality than their counterparts who elect immediate curative treatment, say researchers from the Johns Hopkins University Brady Urological Institute, Baltimore.
After a median of 2 years in an active surveillance cohort being followed with multiparametric-magnetic resonance imaging and MRI-transrectal ultrasound fusion-guided biopsy (“targeted biopsy”), rates of biopsy-proven pathologic progression are similar among men with low-risk and intermediate-risk disease, say researchers from the National Institutes of Health.
Among men who are potent and have low-risk prostate cancer, focal cryotherapy appears to deliver similar oncologic control but with much better recovery of erectile function than a whole-gland approach, according to an analysis using data from the Cryo On-Line Data Registry.
Here are the AUA 2015 take-home messages on sexual/dysfunction, presented by Landon Trost, MD.
Two recently published studies significantly contribute to current knowledge regarding testosterone therapy and cardiovascular health, says one expert urologist.
The cost of radiation therapy for prostate cancer in the United States varies substantially, and most of the variation is accounted for by factors that are not related to the patient or tumor, according to the results of a study published online in Journal of Oncology Practice (Aug. 11, 2015).
A newly identified subset of prostate cancer biomarkers could help explain why African-American men are more likely than European-American men to develop and die from prostate cancer.
Middle-aged and older men undergoing testosterone replacement therapy aren’t at increased risk of venous thromboembolism (VTE), the results of a large comparative case-control analysis published online in Mayo Clinic Proceedings (July 15, 2015) suggest.
A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.
